Experience developing national evidence-based clinical guidelines for childhood pneumonia in a low-income setting - making the GRADE?

BMC Pediatrics

Volumn 12, Issue , 2012, Pages

  Agweyu, Ambrose ^a   Opiyo, Newton ^a   English, Mike ^a,b  

^a KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; CEFTRIAXONE; CHLORAMPHENICOL; COTRIMOXAZOLE; GENTAMICIN; PENICILLIN G; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ANTIBIOTIC THERAPY; CHILDHOOD DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; EVIDENCE BASED PRACTICE; HUMAN; KENYA; LETTER; LOWEST INCOME GROUP; MONOTHERAPY; NON SEVERE PNEUMONIA; OUTCOME ASSESSMENT; PNEUMONIA; SEVERE PNEUMONIA; STRUCTURED QUESTIONNAIRE; SYSTEMATIC REVIEW; VERY SEVERE PNEUMONIA; BACTERIAL PNEUMONIA; CHILD; DEVELOPING COUNTRY; EVIDENCE BASED MEDICINE; METHODOLOGY; PRACTICE GUIDELINE; REVIEW; STANDARD;

AMOXICILLIN; CEFTRIAXONE; CHILD; DEVELOPING COUNTRIES; EVIDENCE-BASED MEDICINE; GENTAMICINS; HUMANS; KENYA; PENICILLIN G; PNEUMONIA, BACTERIAL; PRACTICE GUIDELINES AS TOPIC; REFERENCE STANDARDS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84855172203     PISSN: None     EISSN: 14712431     Source Type: Journal    
DOI: 10.1186/1471-2431-12-1     Document Type: Letter

References (46)

1. National Institute for Health and Clinical Excellence (NICE). , http://www.nice.org.uk/
2. Agency for Healthcare Research and Quality (AHRQ). , http://www.ahrq.gov/
3. The Norwegian Knowledge Centre for the Health Services (NOKC). , http://www.kunnskapssenteret.no/Home
4. Oxman AD, Fretheim A, Schunemann HJ. Improving the use of research evidence in guideline development: introduction. Health Res Policy Syst 2006, 4:12. 10.1186/1478-4505-4-12, 1684247, 17116254.
5. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Working Group. , http://www.gradeworkinggroup.org
6. Guidelines for Development of WHO Guidelines. , http://whqlibdoc.who.int/hq/2003/EIP_GPE_EQC_2003_1.pdf
7. Barbui C, Dua T, van Ommeren M, Yasamy MT, Fleischmann A, Clark N, Thornicroft G, Hill S, Saxena S. Challenges in developing evidence-based recommendations using the GRADE approach: the case of mental, neurological, and substance use disorders. PLoS Med 2010, 7(8).
8. Ansari MT, Tsertsvadze A, Moher D. Grading quality of evidence and strength of recommendations: a perspective. PLoS Med 2009, 6(9):e1000151. 10.1371/journal.pmed.1000151, 2735783, 19753108.
9. Hirsh J, Guyatt G. Clinical experts or methodologists to write clinical guidelines?. Lancet 2009, 374(9686):273-275. 10.1016/S0140-6736(09)60787-X, 19394076.
10. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, Jha P, Campbell H, Walker CF, Cibulskis R, Eisele T, Liu L, Mathers C. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 375(9730):1969-1987.
11. Government of Kenya Basic paediatric protocols. Ministry of Health 2005, Government of Kenya.
12. Scott JA, English M. What are the implications for childhood pneumonia of successfully introducing Hib and pneumococcal vaccines in developing countries?. PLoS Med 2008, 5(4):e86. 10.1371/journal.pmed.0050086, 2292749, 19226734.
13. English M, Esamai E, Wasunna A, Were F, Ogutu B, Wamae A, Snow RW, Peshu N. Delivery of paediatric care at the first-referral level in Kenya. The Lancet 2004, 364:1622-1629.
14. Barbui C, Dua T, van Ommeren M, Yasamy MT, Fleischmann A, Clark N, Thornicroft G, Hill S, Saxena S. Challenges in developing evidence-based recommendations using the GRADE approach: the case of mental, neurological, and substance use disorders. PLoS Med 7(8).
15. WHO Technical updates of the guidelines on the Integrated Management of Childhood Illnesses (IMCI): Evidence and recommendations for further adaptations. 2005, Geneva, Switzerland: WHO, WHO.
16. GRADEpro. , http://ims.cochrane.org/revman/gradepro
17. Kabra SK, Lodha R, Pandey RM. Antibiotics for community-acquired pneumonia in children. Cochrane Database Syst Rev 2010, 3:CD004874.
18. Child Health Evidence Week [Improving delivery of hospital care for infants and newborns in Africa (idoc-Africa website)]. , http://idoc-africa.org
19. Kabra SK, Lodha R, Pandey RM. Antibiotics for community acquired pneumonia in children. Cochrane Database Syst Rev 2006, 3:CD004874.
20. Ayieko P, English M. Case management of childhood pneumonia in developing countries. Pediatr Infect Dis J 2007, 26(5):432-440. 10.1097/01.inf.0000260107.79355.7d, 2654069, 17468655.
21. Grant GB, Campbell H, Dowell SF, Graham SM, Klugman KP, Mulholland EK, Steinhoff M, Weber MW, Qazi S. Recommendations for treatment of childhood non-severe pneumonia. Lancet Infect Dis 2009, 9(3):185-196. 10.1016/S1473-3099(09)70044-1, 19246022.
22. Straus WL, Qazi SA, Kundi Z, Nomani NK, Schwartz B. Antimicrobial resistance and clinical effectiveness of co-trimoxazole versus amoxycillin for pneumonia among children in Pakistan: randomised controlled trial. Pakistan Co-trimoxazole Study Group. Lancet 1998, 352(9124):270-274. 10.1016/S0140-6736(97)10294-X, 9690406.
23. CATCHUP Clinical efficacy of co-trimoxazole versus amoxicillin twice daily for treatment of pneumonia: a randomised controlled clinical trial in Pakistan. Arch Dis Child 2002, 86(2):113-118. 1761064, 11827905, CATCHUP.
24. Awasthi S, Agarwal G, Singh JV, Kabra SK, Pillai RM, Singhi S, Nongkynrih B, Dwivedi R, More VB, Kulkarni M, Niswade AK, Bharti B, Ambast A, Dhasmana P. Effectiveness of 3-day amoxycillin vs. 5-day co-trimoxazole in the treatment of non-severe pneumonia in children aged 2-59 months of age: a multi-centric open labeled trial. J Trop Pediatr 2008, 54(6):382-389. 10.1093/tropej/fmn050, 18611959.
25. Addo-Yobo E, Chisaka N, Hassan M, Hibberd P, Lozano JM, Jeena P, MacLeod WB, Maulen I, Patel A, Qazi S, Thea DM, Nguyen NT. Oral amoxicillin versus injectable penicillin for severe pneumonia in children aged 3 to 59 months: a randomised multicentre equivalency study. Lancet 2004, 364(9440):1141-1148. 10.1016/S0140-6736(04)17100-6, 15451221.
26. Rojas MX, Granados C. Oral antibiotics versus parenteral antibiotics for severe pneumonia in children. Cochrane Database Syst Rev 2006, (2):CD004979.
27. Atkinson M, Lakhanpaul M, Smyth A, Vyas H, Weston V, Sithole J, Owen V, Halliday K, Sammons H, Crane J, Guntupalli N, Walton L, Ninan T, Morjaria A, Stephenson T. Comparison of oral amoxicillin and intravenous benzyl penicillin for community acquired pneumonia in children (PIVOT trial): a multicentre pragmatic randomised controlled equivalence trial. Thorax 2007, 62(12):1102-1106. 10.1136/thx.2006.074906, 2094276, 17567657.
28. Hazir T, Fox LM, Nisar YB, Fox MP, Ashraf YP, MacLeod WB, Ramzan A, Maqbool S, Masood T, Hussain W, Murtaza A, Khawar N, Tariq P, Asghar R, Simon JL, Thea DM, Qazi SA. Ambulatory short-course high-dose oral amoxicillin for treatment of severe pneumonia in children: a randomised equivalency trial. Lancet 2008, 371(9606):49-56. 10.1016/S0140-6736(08)60071-9, 18177775.
29. Hasali MA, Ibrahim MI, Sulaiman SA, Ahmad Z, Hasali JB. A clinical and economic study of community-acquired pneumonia between single versus combination therapy. Pharmacy world & science: PWS 2005, 249-253.
30. Duke T, Poka H, Dale F, Michael A, Mgone J, Wal T. Chloramphenicol versus benzylpenicillin and gentamicin for the treatment of severe pneumonia in children in Papua New Guinea: a randomised trial. Lancet 2002, 359(9305):474-480. 10.1016/S0140-6736(02)07677-8, 11853793.
31. Asghar R, Banajeh S, Egas J, Hibberd P, Iqbal I, Katep-Bwalya M, Kundi Z, Law P, MacLeod W, Maulen-Radovan I, Mino G, Saha S, Sempertegui F, Simon J, Santosham M, Singhi S, Thea DM, Qazi S. Chloramphenicol versus ampicillin plus gentamicin for community acquired very severe pneumonia among children aged 2-59 months in low resource settings: multicentre randomised controlled trial (SPEAR study). BMJ 2008, 336(7635):80-84. 10.1136/bmj.39421.435949.BE, 2190277, 18182412.
32. Cetinkaya F, Gogremis A, Kutluk G. Comparison of two antibiotic regimens in the empirical treatment of severe childhood pneumonia. Indian journal of pediatrics 2004, 969-972.
33. Bansal A, Singhi SC, Jayashree M. Penicillin and gentamicin therapy vs amoxicillin/clavulanate in severe hypoxemic pneumonia. Indian J Pediatr 2006, 73(4):305-309. 10.1007/BF02825824, 16816491.
34. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, Jha P, Campbell H, Walker CF, Cibulskis R, Eisele T, Liu L, Mathers C. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010,
35. Jeena PM, Minkara AK, Corr P, Bassa F, McNally LM, Coovadia HM, Fox M, Hamer DH, Thea D. Impact of HIV-1 status on the radiological presentation and clinical outcome of children with WHO defined community-acquired severe pneumonia. Arch Dis Child 2007, 92(11):976-979. 10.1136/adc.2006.104406, 2083594, 17595201.
36. McNally LM, Jeena PM, Gajee K, Thula SA, Sturm AW, Cassol S, Tomkins AM, Coovadia HM, Goldblatt D. Effect of age, polymicrobial disease, and maternal HIV status on treatment response and cause of severe pneumonia in South African children: a prospective descriptive study. Lancet 2007, 369(9571):1440-1451. 10.1016/S0140-6736(07)60670-9, 17467514.
37. Clifford V, Tebruegge M, Vandeleur M, Curtis N. Question 3: can pneumonia caused by penicillin-resistant Streptococcus pneumoniae be treated with penicillin?. Arch Dis Child 95(1):73-77.
38. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, Alderson P, Glasziou P, Falck-Ytter Y, Schunemann HJ. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 64(4):395-400.
39. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev 2009, (3):CD007483.
40. Jaeschke R, Guyatt GH, Dellinger P, Schunemann H, Levy MM, Kunz R, Norris S, Bion J. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. Bmj 2008, 337:a744. 10.1136/bmj.a744, 18669566.
41. English M, Opiyo N. Getting to grips with GRADE-perspective from a low-income setting. J Clin Epidemiol 2011, 64(7):708-710. 10.1016/j.jclinepi.2010.07.016, 21316192.
42. Fretheim A, Schunemann HJ, Oxman AD. Improving the use of research evidence in guideline development: 5. Group processes. Health Res Policy Syst 2006, 4:17. 10.1186/1478-4505-4-17, 1702534, 17140442.
43. Fretheim A, Schunemann HJ, Oxman AD. Improving the use of research evidence in guideline development: 3. Group composition and consultation process. Health Res Policy Syst 2006, 4:15. 10.1186/1478-4505-4-15, 1702349, 17134482.
44. Raine R, Sanderson C, Hutchings A, Carter S, Larkin K, Black N. An experimental study of determinants of group judgments in clinical guideline development. Lancet 2004, 364(9432):429-437. 10.1016/S0140-6736(04)16766-4, 15288741.
45. Scott IA, Guyatt GH. Clinical practice guidelines: the need for greater transparency in formulating recommendations. Med J Aust 2011, 195(1):29-33.
46. Oxman AD, Lavis JN, Fretheim A. Use of evidence in WHO recommendations. Lancet 2007, 369(9576):1883-1889. 10.1016/S0140-6736(07)60675-8, 17493676.